Valuation: Omeros Corporation

Market Cap 1.33B 1.19B 1.11B 1.01B 1.89B 126B 1.93B 13.29B 5.2B 65.93B 5.01B 4.9B 211B P/E 2026 *
20.3x
P/E 2027 * 17.4x
Enterprise Value 1.33B 1.19B 1.11B 1.01B 1.89B 126B 1.93B 13.29B 5.2B 65.93B 5.01B 4.9B 211B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.03x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.98%
1 week-1.70%
Current month-1.29%
1 month+9.46%
3 months+81.24%
6 months+53.43%
Current year+9.43%
1 week 18.3
Extreme 18.3
20.24
1 month 17.14
Extreme 17.145
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 6.24
Extreme 6.24
21.24
3 years 0.92
Extreme 0.92
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap. Importance
23/9/26 Exercice

Chief Financial Officer

30,000 0.0414%
31/8/26 Exercice

General Counsel

75,000 0.1036%
27/8/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%-1.70%+80.37%+1,120.45% 1.33B
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%+7.51%+8.12%+61.40% 51.9B
+3.14%+7.17%+12.48%+41.70% 48.73B
+3.53%+4.64%+33.36%+36.14% 43.13B
-2.23%+0.59%+281.83%+454.62% 41.48B
+6.49%+6.87%+18.35%+115.12% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.76%-2.00%-13.53%-6.96% 22.27B
Average +1.53%-3.68%+53.51%+193.80% 37.43B
Weighted average by Cap. +1.55%-3.48%+54.35%+101.10%

Financials

2026 *2027 *
Net sales 128M 114M 106M 96.21M 181M 12.08B 184M 1.27B 497M 6.3B 478M 468M 20.16B 221M 198M 184M 167M 314M 20.96B 320M 2.21B 863M 10.94B 831M 813M 35B
Net income 64.97M 57.99M 53.9M 49.02M 92.23M 6.15B 93.9M 647M 253M 3.21B 244M 239M 10.27B 84.8M 75.69M 70.35M 63.99M 120M 8.03B 123M 845M 331M 4.19B 318M 311M 13.41B
Net Debt - -
Projected Income Statement - Annual - Omeros Corporation
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
16/10/26 US$18.79 +1.95% 744,734
14/10/26 US$18.43 -2.38% 905,106
13/10/26 US$18.88 -3.82% 994,056
12/10/26 US$19.63 -1.01% 1,065,300
09/10/26 US$19.83 +3.71% 793,932
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Omeros Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
18.43USD
Average target price
27.50USD
Spread / Average Target
+49.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Omeros Corporation
  1. Stock Market
  2. Stocks
  3. OMER Stock